UroGen Pharma Ltd. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q2 2018 to Q2 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
UroGen Pharma Ltd. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q2 2018 to Q2 2025.
- UroGen Pharma Ltd. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2025 was -$49.9M, a 49.6% decline year-over-year.
- UroGen Pharma Ltd. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending June 30, 2025 was -$155M, a 36.6% decline year-over-year.
- UroGen Pharma Ltd. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was -$127M, a 24.2% decline from 2023.
- UroGen Pharma Ltd. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$102M, a 7.05% increase from 2022.
- UroGen Pharma Ltd. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$110M, a 1.13% increase from 2021.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)